What is the revenue and EPS growth rate for Immunovant year over year?

What guidance did Immunovant's management provide for the next earnings period?

What is the market's earnings forecast for Immunovant next quarter?

What does Immunovant do and what are its main business segments?

What were the key takeaways from Immunovant's earnings call?

What were the key takeaways from Immunovant’s earnings call?

What factors drove the changes in Immunovant's revenue and profit?

Did Immunovant beat or miss consensus estimates last quarter?

- **Phase II Breakthrough in CS**: Brepocitinib demonstrated 21.6-point CSAMI improvement (p < 0.001), with 100% high-dose patients achieving ≥10-point improvement.
- **2026 Catalysts**: Phase III CS trial, Moderna trial, and mosli data in PH-ILD expected to drive 2026 growth.
- **Financial Strength**: $4.5B cash to support pipeline expansion and strategic initiatives.

**【CEO Summary Section】**
- Roivant announced positive Phase II results for brepocitinib in cutaneous sarcoidosis (CS), showing a 21.6-point CSAMI improvement (p < 0.001) with 100% of high-dose patients achieving ≥10-point improvement.
- The company highlighted 2026 as a catalyst-rich year, including the Phase III brepocitinib trial in CS, the Moderna trial starting March 9, and mosliciguat (mosli) Phase II data in PH-ILD.
- Financial strength with $4.5 billion in consolidated cash, supporting multiple pivotal studies and launches.

**【CFO Financial Commentary】**
- Q3 2025 R&D expenses: $165M (GAAP), $147M (non-GAAP); G&A: $175M (GAAP), $71M (non-GAAP).
- Strong cash position ($4.5B) to fund pipeline expansion and strategic initiatives.

**【Q&A Highlights】**
- Brepocitinib Phase II CS data: 100% high-dose patients achieved ≥10-point CSAMI improvement, with safety consistent across trials.
- Moderna trial updates: favorable Section 1498 decision, covering ~90% of asserted doses.
- Pipeline momentum: fully enrolled studies for IMVT-1402 (RA), mosli (PH-ILD), and brepocitinib (DM, NIU).

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

- **DM Market Leader**: Brepocitinib Phase III data positions as first novel oral DM therapy with 30mg dose showing 1/3 patients off steroids. NDA filing Q1 2026.
- **Graves’ Innovation**: Batoclimab delivers 6-month remission in 81% of patients, with 75% off/low ATD use. FcRn mechanism validated by argenx’s VYVGART follow-on.
- **Litigation Catalyst**: Moderna trial March 2026; favorable Pfizer ruling. Global LNP enforcement could unlock $5B+ damages.
- **Pipeline Expansion**: 11 registrational trials across 6 indications. Sjögren’s Phase II targeting ESSDAI; Pulmovant PH-ILD data H2 2026.
- **Capital Strength**: $4.4B cash to fund pipeline through profitability; $500M buyback authorization.


**【CEO Summary Section】**
- **Brepocitinib Phase III Success**: VALOR trial in dermatomyositis (DM) met all endpoints with 30mg dose showing rapid, deep responses across muscle and skin metrics. 1/3 of patients achieved TIS40 and minimal/no steroid use at week 52. NDA filing for DM expected Q1 2026.
- **Graves' Disease Breakthrough**: Batoclimab showed durable remission in 17/21 patients off therapy for 6 months, with 75% off/low ATD use. Data supports disease-modifying potential via deep IgG suppression.
- **Financial Strength**: $4.4B cash, no debt. Strong pipeline with 11 registrational trials across DM, Graves', MG, CIDP, Sjögren’s, and RA.
- **Litigation Progress**: Favorable ruling in Pfizer case; Moderna trial set for March 2026. International cases progressing in UPC, Canada, Japan.
- **Upcoming Events**: Investor Day on Dec 11, 2025 to detail commercial strategy and pipeline updates.

**【Q&A Key Highlights】**
- **Competitive Landscape**: Argenx’s VYVGART in Graves’ validates FcRn strategy. Roivant’s higher IgG reduction (≥70%) in Phase II linked to better ATD discontinuation rates. FcRn safety/tolerability优势 in Graves’ seen as key differentiator.
- **Sjögren’s & Other Indications**: IMVT-1402 Phase II in Sjögren’s targeting ESSDAI; potential first-in-class with deeper IgG suppression. Pulmovant’s mosli for PH-ILD Phase IIb data expected H2 2026.
- **LNP Litigation**: Moderna U.S. sales <50% of global; 1498 patent defense scope narrow. International trials could yield decisions in 2026.
- **DM Launch Strategy**: No direct analogs; focus on unmet need in DM with oral, scalable therapy. Global enrollment in NIU trial progressing.
- **Ted Study**: Delayed data release to align with evolving competitive landscape. Focus on Graves’ as upstream opportunity.


Actual	-0.38	-0.38	-0.25	-0.32	-0.29	-0.31	-0.35	-0.36	-0.41	-0.35	-0.41	-0.49	-0.46	-0.57	-0.45	-0.2894	-0.52	-0.6	-0.74	-0.76	-0.64	-0.71	-0.73	-0.5378
Forecast	-0.41	-0.328	-0.312	-0.2532	-0.3275	-0.31	-0.2629	-0.3188	-0.3617	-0.3745	-0.3701	-0.3731	-0.4228	-0.4463	-0.4581	-0.4278	-0.4296	-0.5306	-0.6002	-0.7517	-0.7133	-0.6804	-0.7142	-0.7134
Surprise	+7.32%	-15.85%	+19.87%	-26.38%	+11.45%	0.00%	-33.13%	-12.92%	-13.35%	+6.54%	-10.78%	-31.33%	-8.80%	-27.72%	+1.77%	+32.35%	-21.04%	-13.08%	-23.29%	-1.10%	+10.28%	-4.35%	-2.21%	+24.61%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

IMVT

IMVT fundamentals

IMVT Q3 2026 Earnings

Earnings Call

You can ask Aime

IMVT

IMVT fundamentals

IMVT Q3 2026 Earnings

Earnings Call

IMVT Earnings Call Summary for Q3/20268:00 AM on Feb 6, 2026

IMVT Earnings Call Summary for Q2/20268:00 AM on Nov 10, 2025

IMVT Earnings Call Summary for Q1/20267:00 AM on Aug 11, 2025

IMVT Earnings Call Summary for Q4/20259:30 AM on May 30, 2025

IMVT Earnings Call Summary for Q3/2025 Apr 2, 2026

You can ask Aime